Founded in 2011
Autifony Therapeutics Ltd
Autifony Therapeutics is an independent UK-based biotechnology company formed in 2011 as a spinout from GSK, which retains equity in the company. The company is focused on the development of high-value, novel medicines to treat serious diseases of the central nervous system. It is funded by SV Life Sciences, Touchstone Innovations plc, Pfizer Venture Investments, International Biotechnology Trust plc, and UCLB.